BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SW1990 cell line is 112
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 20372854 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.1739 | 20372854 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.1739 | 31508487 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.1739 | 30819221 |
| ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.48 | 0.1739 | 30466404 |
| BMI1 | 1066 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.1135 | 27576197 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 33737813 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5461 | 27576197 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5461 | 31508487 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SFA and qPCR | NA | 0.48 | 0.5461 | 30954649 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.48 | 0.5461 | 33288882 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 30954649 |
| NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 26439804 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 33737813 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SFA and qPCR | NA | 0.48 | 0.6448 | 30954649 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.6448 | 32781084 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Tumorigenicity assay and Western Blotting | NA | 0.48 | 0.6448 | 25003666 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.6448 | 26391180 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.6448 | 31508487 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 30954649 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.48 | 0.6448 | 30819221 |
| POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SP assay | NA | 0.48 | 0.6448 | 22963768 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 33737813 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 27576197 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR followed by Western Blotting | NA | 0.48 | 0.5695 | 31508487 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SFA and qPCR | NA | 0.48 | 0.5695 | 30954649 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.48 | 0.5695 | 33288882 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.48 | 0.5695 | 32781084 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.48 | 0.5695 | 26391180 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 30954649 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 28947139 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 26439804 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.48 | 0.5695 | 30466404 |
| SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SP assay | NA | 0.48 | 0.5695 | 22963768 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay and ALDEFLUOR assay followed by Western Blotting and SFA | NA | 0.4 | 0.684 | 32781084 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.4 | 0.684 | 33288882 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Tumorigenicity assay and Western Blotting | NA | 0.4 | 0.684 | 25003666 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.4 | 0.684 | 31508487 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.4 | 0.684 | 28947139 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | ALDEFLUOR assay | NA | 0.4 | 0.684 | 30954649 |
| ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by FACs | NA | 0.4 | 0.684 | 26439804 |
| THY1 | 11801 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SFA and qPCR | NA | 0.32 | 0.0371 | 30954649 |
| THY1 | 11801 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR and FACs | NA | 0.32 | 0.0371 | 30954649 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.456 | 32781084 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.28 | 0.456 | 31508487 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | FACs | NA | 0.28 | 0.456 | 22322379 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs | NA | 0.28 | 0.456 | 27734340 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SP assay | NA | 0.28 | 0.456 | 22963768 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.456 | 20372854 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.456 | 20372854 |
| CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.456 | 30819221 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 1 | 33288882 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 1 | 32781084 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.28 | 1 | 28947139 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.28 | 1 | 26439804 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 1 | 30466404 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 1 | 30466404 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | FACs | NA | 0.28 | 1 | 22322379 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs | NA | 0.28 | 1 | 27734340 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | FACs followed by SFA | NA | 0.28 | 1 | 27576197 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SP assay | NA | 0.28 | 1 | 22963768 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 1 | 20372854 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 1 | 20372854 |
| CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 1 | 30819221 |
| CTNNB1 | 2514 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0647 | 32781084 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 0.211 | 33288882 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.211 | 32781084 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.28 | 0.211 | 31508487 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.211 | 26439804 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 0.211 | 30466404 |
| EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs followed by SP assay | NA | 0.28 | 0.211 | 22963768 |
| PAF1 | 25459 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0032 | 32781084 |
| PAF1 | 25459 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Tumorigenicity assay and Western Blotting | NA | 0.28 | 0.0032 | 25003666 |
| PAF1 | 25459 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 0.0032 | 25003666 |
| PHF5A | 18000 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0011 | 32781084 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Tumorigenicity assay and Western Blotting | NA | 0.28 | 0.7582 | 25003666 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.28 | 0.7582 | 28947139 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.28 | 0.7582 | 30819221 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | FACs | NA | 0.28 | 0.7582 | 26391180 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs | NA | 0.28 | 0.7582 | 29344263 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | FACs | NA | 0.28 | 0.7582 | 31669811 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | FACs followed by SFA | NA | 0.28 | 0.7582 | 27576197 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by FACs | NA | 0.28 | 0.7582 | 26439804 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.7582 | 20372854 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.7582 | 20372854 |
| PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by FACs | NA | 0.28 | 0.7582 | 22030254 |
| SHH | 10848 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 0.0201 | 33288882 |
| SHH | 10848 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 0.0201 | 25003666 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting | NA | 0.28 | 0.0244 | 33288882 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by Western Blotting and SFA | NA | 0.28 | 0.0244 | 32781084 |
| SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by SFA and qRT-PCR | NA | 0.28 | 0.0244 | 30466404 |
| STAT3 | 11364 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | Western Blotting followed by SFA | NA | 0.28 | 0.0223 | 27576197 |
| B3GNT2 | 15629 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0011 | 30466404 |
| B3GNT3 | 13528 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0042 | 30466404 |
| GALNT12 | 19877 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0032 | 30466404 |
| GALNT16 | 23233 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0021 | 30466404 |
| GALNT3 | 4125 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0042 | 30466404 |
| MGAT4A | 7047 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by PCR array assay and qRT-PCR | Up | 0.24 | 0.0032 | 30466404 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0604 | 31508487 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0604 | 20372854 |
| ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0604 | 20372854 |
| ABCC1 | 51 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0212 | 20372854 |
| ABCC1 | 51 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0212 | 20372854 |
| ACVR1 | 171 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0011 | 30819221 |
| CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0498 | 31508487 |
| HOTAIR | 33510 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 33737813 |
| HOTTIP | 37461 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0011 | 28947139 |
| KLF4 | 6348 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0891 | 31508487 |
| KRT19 | 6436 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0074 | 30819221 |
| LIN28A | 15986 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0138 | 28947139 |
| MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | Gemcitabine | qRT-PCR | NA | 0.2 | 0.0191 | 26391180 |
| NES | 7756 | LTM | Pancreatic Cancer | Adenocarcinoma | SW1990 | NA | SP assay followed by qRT-PCR | NA | 0.2 | 0.0573 | 30819221 |